Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Author(s): ">Giuseppe Lisco*, Anna De Tullio, Edoardo Guastamacchia and Vincenzo Triggiani

DOI: 10.2174/1871530320666200705211224

DownloadDownload PDF Flyer Cite As
Fixed-Ratio Combinations of Basal Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from the Literature

Page: [626 - 646] Pages: 21

  • * (Excluding Mailing and Handling)

Abstract

New pieces of evidence suggest that combining basal insulin with glucagone-like peptide 1 receptor agonists (GLP-1RA) in patients with type 2 diabetes could promptly ameliorate glucose control and prevent both hypoglycemic events and unnecessary weight gain compared to more intensive insulin regimens.

To review the efficacy/effectiveness and safety of fixed-ratio combinations of basal insulin and GLP- 1RA (FRCs).

Authors searched PubMed/MEDLINE, ClinicalTrials.gov, Cochrane Library, and Google Scholar for freely available original articles, randomized clinical trials (RCTs), clinical reviews, and meta-analysis written in English until January 2020.

FRCs provide significative reductions in HbA1c levels in both insulin-naïve (-1.4% to -2%) and insulin- experienced (-1.5% to -2%) type 2 diabetic patients with moderate glucose impairment. More patients achieved the recommended glycemic targets on FRCs compared to those on mono-therapy with basal insulin or GLP-1RAs. The intensification with FRCs results in better glycemic control compared to basal insulin at fasting as well as during the postprandial state. The frequency of hypoglycemia is similar or lower in patients treated with FRCs than in those on basal insulin alone at a similar dose. Weight trend can be variable, ranging from -2.7 to +2 Kg for iDegLira and -0.7 to -1.3 Kg for iGlar- Lixi. However, a lower weight gain is obtained with iDegLira compared to iDeg (-2.2 to -2.5 Kg), iGlar (-1.7 to -3.2 Kg), and basal-bolus (-3.6 Kg) as well as with iGlarLixi compared to iGlar (-1.4 Kg).

FRCs should be considered to safely improve the metabolic control in type 2 diabetic patients with moderate glycemic impairment while on oral medications, basal oral regimen or GLP-1RAs. However, a few but significative pieces of evidence suggest that FRCs could be a safe and effective treatment instead of a low dose basal-bolus intensification for patients with mild or moderate glucose impairment in order to reduce the risk of hypoglycemia and unnecessary weight gain, and for simplifying treatment regimen as well.

Keywords: Basal insulin, insulin regimens, GLP-1RA, insulin degludec plus liraglutide, insulin glargine plus lixisenatide, iDegLira, iGlarLixi.

Graphical Abstract

[1]
Chang-Chen, K.J.; Mullur, R.; Bernal-Mizrachi, E. β-cell failure as a complication of diabetes. Rev. Endocr. Metab. Disord., 2008, 9(4), 329-343.
[http://dx.doi.org/10.1007/s11154-008-9101-5] [PMID: 18777097]
[2]
Dalal, M.R.; Grabner, M.; Bonine, N.; Stephenson, J.J.; DiGenio, A.; Bieszk, N. Are patients on basal insulin attaining glycemic targets? Characteristics and goal achievement of patients with type 2 diabetes mellitus treated with basal insulin and physician-perceived barriers to achieving glycemic targets. Diabetes Res. Clin. Pract., 2016, 121, 17-26.
[http://dx.doi.org/10.1016/j.diabres.2016.08.004] [PMID: 27616634]
[3]
Kalra, S.; Gupta, Y. Basal insulin inadequacy versus failure - using appropriate terminology. Eur Endocrinol, 2015, 11(2), 79-80.
[http://dx.doi.org/10.17925/EE.2015.11.02.79] [PMID: 29632574]
[4]
Rowlands, J.; Heng, J.; Newsholme, P.; Carlessi, R. Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function. Front. Endocrinol. (Lausanne), 2018, 9, 672.
[http://dx.doi.org/10.3389/fendo.2018.00672] [PMID: 30532733]
[5]
Hinnen, D. Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectr., 2017, 30(3), 202-210.
[http://dx.doi.org/10.2337/ds16-0026] [PMID: 28848315]
[6]
Anderson, S.L.; Trujillo, J.M. Basal insulin use with GLP-1 receptor agonists. Diabetes Spectr., 2016, 29(3), 152-160.
[http://dx.doi.org/10.2337/diaspect.29.3.152] [PMID: 27574369]
[7]
Blonde, L.; Anderson, J.E.; Chava, P.; Dendy, J.A. Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes. Curr. Med. Res. Opin., 2019, 35(5), 793-804.
[http://dx.doi.org/10.1080/03007995.2018.1541790] [PMID: 30370783]
[8]
Mathieu, C.; Rodbard, H.W.; Cariou, B.; Handelsman, Y.; Philis-Tsimikas, A.; Ocampo Francisco, A.M.; Rana, A.; Zinman, B. BEGIN: VICTOZA ADD-ON (NN1250-3948) study group. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes. Metab., 2014, 16(7), 636-644.
[http://dx.doi.org/10.1111/dom.12262] [PMID: 24443830]
[9]
Guja, C.; Frías, J.P.; Somogyi, A.; Jabbour, S.; Wang, H.; Hardy, E.; Rosenstock, J. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: the duration-7 randomized study. Diabetes Obes. Metab., 2018, 20(7), 1602-1614.
[http://dx.doi.org/10.1111/dom.13266] [PMID: 29473704]
[10]
Pantalone, K.M.; Patel, H.; Yu, M.; Fernández Landó, L. Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration. Diabetes Obes. Metab., 2018, 20(6), 1461-1469.
[http://dx.doi.org/10.1111/dom.13252] [PMID: 29430801]
[11]
Yu, M.; Brunt, K.V.; Milicevic, Z.; Varnado, O.; Boye, K.S. Patient-reported outcomes in patients with type 2 diabetes treated with dulaglutide added to titrated insulin Glargine (AWARD-9). Clin. Ther., 2017, 39(11), 2284-2295.
[http://dx.doi.org/10.1016/j.clinthera.2017.10.002] [PMID: 29110972]
[12]
Rosenstock, J.; Guerci, B.; Hanefeld, M.; Gentile, S.; Aronson, R.; Tinahones, F.J.; Roy-Duval, C.; Souhami, E.; Wardecki, M.; Ye, J.; Perfetti, R.; Heller, S. Prandial options to advance basal insulin glargine therapy: testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 diabetes: The GetGoal Duo-2 Trial. Diabetes Care, 2016, 39(8), 1318-1328.
[http://dx.doi.org/10.2337/dc16-0014] [PMID: 27222510]
[13]
Diamant, M.; Nauck, M.A.; Shaginian, R.; Malone, J.K.; Cleall, S.; Reaney, M.; de Vries, D.; Hoogwerf, B.J.; MacConell, L.; Wolffenbuttel, B.H. 4B Study Group. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care, 2014, 37(10), 2763-2773.
[http://dx.doi.org/10.2337/dc14-0876] [PMID: 25011946]
[14]
Buse, J.B.; Han, J.; Miller, S.; MacConell, L.; Pencek, R.; Wintle, M. Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration. Curr. Med. Res. Opin., 2014, 30(7), 1209-1218.
[http://dx.doi.org/10.1185/03007995.2014.896329] [PMID: 24621255]
[15]
Riddle, M.C.; Forst, T.; Aronson, R.; Sauque-Reyna, L.; Souhami, E.; Silvestre, L.; Ping, L.; Rosenstock, J. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care, 2013, 36(9), 2497-2503.
[http://dx.doi.org/10.2337/dc12-2462] [PMID: 23564915]
[16]
Rodbard, H.W.; Lingvay, I.; Reed, J.; de la Rosa, R.; Rose, L.; Sugimoto, D.; Araki, E.; Chu, P.L.; Wijayasinghe, N.; Norwood, P. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J. Clin. Endocrinol. Metab., 2018, 103(6), 2291-2301.
[http://dx.doi.org/10.1210/jc.2018-00070] [PMID: 29688502]
[17]
Castellana, M.; Cignarelli, A.; Brescia, F.; Laviola, L.; Giorgino, F. GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab. Res. Rev., 2019, 35(1)e3082
[http://dx.doi.org/10.1002/dmrr.3082] [PMID: 30270567]
[18]
Maiorino, M.I.; Chiodini, P.; Bellastella, G.; Capuano, A.; Esposito, K.; Giugliano, D. Insulin and glucagon-like peptide 1 receptor agonist combination therapy in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care, 2017, 40(4), 614-624.
[http://dx.doi.org/10.2337/dc16-1957] [PMID: 28325801]
[19]
Garber, A. J. ONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2019 EXECUTIVE SUMMARY Tullis Tulane Alumni Chair in Diabetes, 2019, 25.
[20]
Xultophy | European Medicines Agency. Available at:. https://www.ema.europa.eu/en/medicines/human/EPAR/xultophy (Accessed 2019).
[21]
Suliqua | European Medicines Agency. Available at:. https://www.ema.europa.eu/en/medicines/human/EPAR/suliqua (Accessed 2019).
[22]
Gough, S.C.L.; Bode, B.; Woo, V.; Rodbard, H.W.; Linjawi, S.; Poulsen, P.; Damgaard, L.H.; Buse, J.B. NN9068-3697 (DUAL-I) trial investigators. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol., 2014, 2(11), 885-893.
[http://dx.doi.org/10.1016/S2213-8587(14)70174-3] [PMID: 25190523]
[23]
Rodbard, H.W.; Bode, B.W.; Harris, S.B.; Rose, L.; Lehmann, L.; Jarlov, H.; Thurman, J. Dual Action of Liraglutide and insulin degludec (DUAL) IV trial investigators. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial. Diabet. Med., 2017, 34(2), 189-196.
[http://dx.doi.org/10.1111/dme.13256] [PMID: 27589252]
[24]
Harris, S.B.; Kocsis, G.; Prager, R.; Ridge, T.; Chandarana, K.; Halladin, N.; Jabbour, S. Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial. Diabetes Obes. Metab., 2017, 19(6), 858-865.
[http://dx.doi.org/10.1111/dom.12892] [PMID: 28124817]
[25]
Aroda, V.R.; González-Galvez, G.; Grøn, R.; Halladin, N.; Haluzík, M.; Jermendy, G.; Kok, A.; Őrsy, P.; Sabbah, M.; Sesti, G.; Silver, R. Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol., 2019, 7(8), 596-605.
[http://dx.doi.org/10.1016/S2213-8587(19)30184-6] [PMID: 31189519]
[26]
Philis-Tsimikas, A.; Billings, L.K.; Busch, R.; Portillo, C.M.; Sahay, R.; Halladin, N.; Eggert, S.; Begtrup, K.; Harris, S. Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: a randomized clinical trial in people with uncontrolled type 2 diabetes. Diabetes Obes. Metab., 2019, 21(6), 1399-1408.
[http://dx.doi.org/10.1111/dom.13666] [PMID: 30761720]
[27]
Linjawi, S.; Bode, B.W.; Chaykin, L.B.; Courrèges, J.P.; Handelsman, Y.; Lehmann, L.M.; Mishra, A.; Simpson, R.W. The efficacy of IDegLira (insulin degludec/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL III randomized clinical trial. Diabetes Ther., 2017, 8(1), 101-114.
[http://dx.doi.org/10.1007/s13300-016-0218-3] [PMID: 27943107]
[28]
Buse, J.B.; Vilsbøll, T.; Thurman, J.; Blevins, T.C.; Langbakke, I.H.; Bøttcher, S.G.; Rodbard, H.W. NN9068-3912 (DUAL-II) trial investigators. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care, 2014, 37(11), 2926-2933.
[http://dx.doi.org/10.2337/dc14-0785] [PMID: 25114296]
[29]
Lingvay, I.; Pérez Manghi, F.; García-Hernández, P.; Norwood, P.; Lehmann, L.; Tarp-Johansen, M.J.; Buse, J.B. DUAL V investigators. Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: The DUAL v randomized clinical trial. JAMA, 2016, 315(9), 898-907.
[http://dx.doi.org/10.1001/jama.2016.1252] [PMID: 26934259]
[30]
Billings, L.K.; Doshi, A.; Gouet, D.; Oviedo, A.; Rodbard, H.W.; Tentolouris, N.; Grøn, R.; Halladin, N.; Jodar, E. Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the dual VII randomized clinical trial. Diabetes Care, 2018, 41(5), 1009-1016.
[http://dx.doi.org/10.2337/dc17-1114] [PMID: 29483185]
[31]
Aroda, V.R.; Rosenstock, J.; Wysham, C.; Unger, J.; Bellido, D.; González-Gálvez, G.; Takami, A.; Guo, H.; Niemoeller, E.; Souhami, E.; Bergenstal, R.M. LixiLan-L trial investigators. Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial. Diabetes Care, 2016, 39(11), 1972-1980.
[http://dx.doi.org/10.2337/dc16-1495] [PMID: 27650977]
[32]
Rosenstock, J. Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: The LixiLan-O randomized trial. Diabetes Care; American Diabetes Association Inc., 2016, Vol. 39, pp. 2026-2035.
[33]
Blonde, L.; Rosenstock, J.; Del Prato, S.; Henry, R.; Shehadeh, N.; Frias, J.; Niemoeller, E.; Souhami, E.; Ji, C.; Aroda, V.R. Switching to iGlarLixi versus continuing daily or weekly GLP-1 RA in type 2 diabetes inadequately controlled by GLP-1 RA and oral antihyperglycemic therapy: the LixiLan-G randomized clinical trial. Diabetes Care, 2019, 42(11), 2108-2116.
[http://dx.doi.org/10.2337/dc19-1357] [PMID: 31530665]
[34]
Wysham, C.; Bonadonna, R.C.; Aroda, V.R.; Puig Domingo, M.; Kapitza, C.; Stager, W.; Yu, C.; Niemoeller, E.; Souhami, E.; Bergenstal, R.M. LixiLan-L trial investigators. Consistent findings in glycemic control, body weight and hypoglycemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial. Diabetes Obes. Metab., 2017, 19(10), 1408-1415.
[http://dx.doi.org/10.1111/dom.12961] [PMID: 28386990]
[35]
Sugimoto, D.H.; Dex, T.; Stager, W.; Aroda, V.R. Efficacy of iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements. Diabetes Obes. Metab., 2018, 20(11), 2680-2684.
[http://dx.doi.org/10.1111/dom.13438] [PMID: 29923361]
[36]
Niemoeller, E.; Souhami, E.; Wu, Y.; Jensen, K.H. iGlarLixi reduces glycated hemoglobin to a greater extent than basal insulin regardless of levels at screening: post hoc analysis of LixiLan-L. Diabetes Ther., 2018, 9(1), 373-382.
[http://dx.doi.org/10.1007/s13300-017-0336-6] [PMID: 29143919]
[37]
Frias, J.; Puig Domingo, M.; Meneghini, L.; Napoli, R.; Liu, M.; Soltes Rak, E.; Aroda, V.R. More patients reach glycemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L. Diabetes Obes. Metab., 2018, 20(9), 2314-2318.
[http://dx.doi.org/10.1111/dom.13368] [PMID: 29785837]
[38]
Pablo Frias, J.; Lorenz, M.; Roberts, M.; Dex, T.; Schmider, W.; Hurst, W.; Skolnik, N. Impact of lixisenatide dose range on clinical outcomes with fixed-ratio combination iGlarLixi in patients with type 2 diabetes. Curr. Med. Res. Opin., 2019, 35(4), 689-695.
[http://dx.doi.org/10.1080/03007995.2018.1541316] [PMID: 30360647]
[39]
Filippatos, T.D.; Panagiotopoulou, T.V.; Elisaf, M.S. Adverse effects of GLP-1 receptor agonists. Rev. Diabet. Stud., 2014, 11(3-4), 202-230.
[http://dx.doi.org/10.1900/RDS.2014.11.202] [PMID: 26177483]
[40]
Trujillo, J.M.; Roberts, M.; Dex, T.; Chao, J.; White, J.; LaSalle, J. Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide alone. Diabetes Obes. Metab., 2018, 20(11), 2690-2694.
[http://dx.doi.org/10.1111/dom.13444] [PMID: 29923298]
[41]
Bettge, K.; Kahle, M.; Abd El Aziz, M.S.; Meier, J.J.; Nauck, M.A. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes. Metab., 2017, 19(3), 336-347.
[http://dx.doi.org/10.1111/dom.12824] [PMID: 27860132]
[42]
Marso, S.P.; McGuire, D.K.; Zinman, B.; Poulter, N.R.; Emerson, S.S.; Pieber, T.R.; Pratley, R.E.; Haahr, P.M.; Lange, M.; Brown-Frandsen, K.; Moses, A.; Skibsted, S.; Kvist, K.; Buse, J.B. DEVOTE study group. Efficacy and safety of degludec versus glargine in type 2 diabetes. N. Engl. J. Med., 2017, 377(8), 723-732.
[http://dx.doi.org/10.1056/NEJMoa1615692] [PMID: 28605603]
[43]
Wysham, C.; Bhargava, A.; Chaykin, L.; de la Rosa, R.; Handelsman, Y.; Troelsen, L.N.; Kvist, K.; Norwood, P. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes the SWITCH 2 randomized clinical trial. JAMA, 2017, 318(1), 45-56.
[http://dx.doi.org/10.1001/jama.2017.7117] [PMID: 28672317]
[44]
Frias, J.P.; Dex, T.; Roberts, M.; Kaplan, A. A review of the safety and adverse event profile of the fixed-ratio combination of insulin glargine and lixisenatide. Diabetes Ther., 2019, 10(1), 21-33.
[http://dx.doi.org/10.1007/s13300-018-0547-5] [PMID: 30539523]
[45]
Rosenstock, J.; Handelsman, Y.; Vidal, J.; Ampudia Blasco, F.J.; Giorgino, F.; Liu, M.; Perfetti, R.; Meier, J.J. Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes. Diabetes Obes. Metab., 2018, 20(12), 2821-2829.
[http://dx.doi.org/10.1111/dom.13462] [PMID: 29974618]
[46]
Drummond, R.; Baru, A.; Dutkiewicz, M.; Basse, A.; Tengmark, B-O. Physicians’ real-world experience with IDegLira: results of a European survey. BMJ Open Diabetes Res. Care, 2018, 6(1)e000531
[http://dx.doi.org/10.1136/bmjdrc-2018-000531] [PMID: 29942526]
[47]
Price, H.; Blüher, M.; Prager, R.; Phan, T.M.; Thorsted, B.L.; Schultes, B. EXTRA study group. Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: results from a European, multicentre, retrospective chart review study. Diabetes Obes. Metab., 2018, 20(4), 954-962.
[http://dx.doi.org/10.1111/dom.13182] [PMID: 29205856]
[48]
Melzer-Cohen, C.; Chodick, G.; Naftelberg, S.; Shehadeh, N.; Karasik, A. Metabolic control and adherence to therapy in type 2 diabetes mellitus patients using IDegLira in a real-world setting. Diabetes Ther., 2019, 11(1), 185-196.
[http://dx.doi.org/10.1007/s13300-019-00725-9] [PMID: 31808132]
[49]
Raya, P.M.; Blasco, F.J.A.; Hunt, B.; Martin, V.; Thorsted, B.L.; Basse, A.; Price, H. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence. Diabetes Obes. Metab., 2019, 21(6), 1349-1356.
[http://dx.doi.org/10.1111/dom.13660] [PMID: 30740861]
[50]
Cannon, A.J. Evaluation of the short-term cost-effectiveness of IDegLira versus basal insulin and basal-bolus therapy in patients with type 2 diabetes based on attainment of clinically relevant treatment targets. J. Manag. Care Spec. Pharm., 2019, 26(2), 1-12.
[http://dx.doi.org/10.18553/jmcp.2019.19035] [PMID: 31856636]
[51]
Drummond, R.; Malkin, S.; Du Preez, M.; Lee, X.Y.; Hunt, B. The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): a short-term cost-effectiveness analysis in the UK setting. Diabetes Obes. Metab., 2018, 20(10), 2371-2378.
[http://dx.doi.org/10.1111/dom.13375] [PMID: 29797389]
[52]
Billings, L.K.; Mocarski, M.; Basse, A.; Hunt, B.; Valentine, W.J.; Jodar, E. Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA. Clinicoecon. Outcomes Res., 2019, 11, 271-282.
[http://dx.doi.org/10.2147/CEOR.S194719] [PMID: 30962697]
[53]
Dempsey, M.; Mocarski, M.; Langer, J.; Hunt, B. IDegLira is associated with improved short-term clinical outcomes and cost savings compared with insulin glargine u100 plus insulin aspart in the U.S. Endocr. Pract., 2018, 24(9), 796-804.
[http://dx.doi.org/10.4158/EP-2018-0134] [PMID: 30308134]
[54]
Dempsey, M.; Mocarski, M.; Langer, J.; Hunt, B. Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US. J. Med. Econ., 2018, 21(11), 1110-1118.
[http://dx.doi.org/10.1080/13696998.2018.1513406] [PMID: 30114954]
[55]
Psota, M.; Psenkova, M.B.; Racekova, N.; Ramirez de Arellano, A.; Vandebrouck, T.; Hunt, B. Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system. Clinicoecon. Outcomes Res., 2017, 9, 749-762.
[http://dx.doi.org/10.2147/CEOR.S143127] [PMID: 29276398]
[56]
Morieri, M.L.; Rigato, M.; Frison, V.; Simioni, N.; D’Ambrosio, M.; Tadiotto, F.; Paccagnella, A.; Lapolla, A.; Avogaro, A.; Fadini, G.P. Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: a retrospective multicentre comparative effectiveness study. Diabetes Obes. Metab., 2019, 21(11), 2542-2552.
[http://dx.doi.org/10.1111/dom.13840] [PMID: 31364233]
[57]
Fu, A.Z.; Sheehan, J.J. Treatment intensification for patients with type 2 diabetes and poor glycemic control. Diabetes Obes. Metab., 2016, 18(9), 892-898.
[http://dx.doi.org/10.1111/dom.12683] [PMID: 27160505]
[58]
Gentile, S.; Ceriello, A.; Strollo, F. START DIAB study group. A multicenter Italian survey on diabetes care units reveals a somewhat slow attitude in treatment guideline implementation: are we dealing with therapeutic inertia? Diabetes Res. -. Open J., 2016, 2(2), 33-44.
[http://dx.doi.org/10.17140/DROJ-2-127]
[59]
Janez, A. Benefits of insulin degludec/liraglutide (IDegLira) are maintained even in patients discontinuing sulphonylurea or dipeptidyl peptidase‐ 4 inhibitor upon initiation of IDegLira therapy: a post hoc analysis of the DUAL II and DUAL IX trials Diabetes, Obes. Metab. dom.13944, 2019, 22(4), 658-668..
[60]
Gough, S.C.L.; Bode, B.W.; Woo, V.C.; Rodbard, H.W.; Linjawi, S.; Zacho, M.; Reiter, P.D.; Buse, J.B. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. Diabetes Obes. Metab., 2015, 17(10), 965-973.
[http://dx.doi.org/10.1111/dom.12498] [PMID: 25980900]
[61]
Davies, M.J.; Russell-Jones, D.; Barber, T.M.; Lavalle-González, F.J.; Galstyan, G.R.; Zhu, D.; Baxter, M.; Dessapt-Baradez, C.; McCrimmon, R.J. Glycemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycemic control on two oral antihyperglycemic drugs in the LixiLan-O randomized trial. Diabetes Obes. Metab., 2019, 21(8), 1967-1972.
[http://dx.doi.org/10.1111/dom.13791] [PMID: 31124299]
[62]
Wysham, C.H.; Campos, C.; Kruger, D. Safety and efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine U100/lixisenatide (iGlarLixi), two novel co-formulations of a basal insulin and a glucagon-like peptide-1 receptor agonist, in patients with diabetes not adequately controlled on oral antidiabetic medications. Clin. Diabetes, 2018, 36(2), 149-159.
[http://dx.doi.org/10.2337/cd17-0064] [PMID: 29686454]
[63]
Freemantle, N.; Mamdani, M.; Vilsbøll, T.; Kongsø, J.H.; Kvist, K.; Bain, S.C. IDegLira versus alternative intensification strategies in patients with type 2 diabetes inadequately controlled on basal insulin therapy. Diabetes Ther., 2015, 6(4), 573-591.
[http://dx.doi.org/10.1007/s13300-015-0142-y] [PMID: 26582052]
[64]
Ahmann, A.; Rodbard, H.W.; Rosenstock, J.; Lahtela, J.T.; de Loredo, L.; Tornøe, K.; Boopalan, A.; Nauck, M.A. NN2211-3917 study group. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes. Metab., 2015, 17(11), 1056-1064.
[http://dx.doi.org/10.1111/dom.12539] [PMID: 26179619]
[65]
DeVries, J.H.; Bain, S.C.; Rodbard, H.W.; Seufert, J.; D’Alessio, D.; Thomsen, A.B.; Zychma, M.; Rosenstock, J. Liraglutide-Detemir study group. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care, 2012, 35(7), 1446-1454.
[http://dx.doi.org/10.2337/dc11-1928] [PMID: 22584132]
[66]
Rosenstock, J.; Rodbard, H.W.; Bain, S.C.; D’Alessio, D.; Seufert, J.; Thomsen, A.B.; Svendsen, C.B.; DeVries, J.H. Liraglutide-Detemir study group. One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target. J. Diabetes Complications, 2013, 27(5), 492-500.
[http://dx.doi.org/10.1016/j.jdiacomp.2013.04.008] [PMID: 23746555]
[67]
Aroda, V.R.; Bailey, T.S.; Cariou, B.; Kumar, S.; Leiter, L.A.; Raskin, P.; Zacho, J.; Andersen, T.H.; Philis-Tsimikas, A. Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study). Diabetes Obes. Metab., 2016, 18(7), 663-670.
[http://dx.doi.org/10.1111/dom.12661] [PMID: 26990378]
[68]
Blonde, L.; Meneghini, L.; Peng, X.V.; Boss, A.; Rhee, K.; Shaunik, A.; Kumar, S.; Balodi, S.; Brulle-Wohlhueter, C.; McCrimmon, R.J. Probability of achieving glycemic control with basal insulin in patients with type 2 diabetes in real-world practice in the USA. Diabetes Ther., 2018, 9(3), 1347-1358.
[http://dx.doi.org/10.1007/s13300-018-0413-5] [PMID: 29600507]
[69]
Chun, J.; Strong, J.; Urquhart, S. Insulin initiation and titration in patients with type 2 diabetes. Diabetes Spectr., 2019, 32(2), 104-111.
[http://dx.doi.org/10.2337/ds18-0005] [PMID: 31168280]
[70]
Zisman, A.; Dex, T.; Roberts, M.; Saremi, A.; Chao, J.; Aroda, V.R. Bedtime-to-morning glucose difference and iGlarLixi in type 2 diabetes: post hoc analysis of LixiLan-L. Diabetes Ther., 2018, 9(5), 2155-2162.
[http://dx.doi.org/10.1007/s13300-018-0507-0] [PMID: 30218434]
[71]
King, A.B.; Philis-Tsimikas, A.; Kilpatrick, E.S.; Langbakke, I.H.; Begtrup, K.; Vilsbøll, T. A Fixed ratio combination of insulin degludec and liraglutide (IDegLira) reduces glycemic fluctuation and brings more patients with type 2 diabetes within blood glucose target ranges. Diabetes Technol. Ther., 2017, 19(4), 255-264.
[http://dx.doi.org/10.1089/dia.2016.0405] [PMID: 28282219]
[72]
Aronson, R.; Umpierrez, G.; Stager, W.; Kovatchev, B. Insulin glargine/lixisenatide fixed-ratio combination improves glycemic variability and control without increasing ypoglycemia. Diabetes Obes. Metab., 2019, 21(3), 726-731.
[PMID: 30421545]
[73]
Lingvay, I.; Harris, S.; Jaeckel, E.; Chandarana, K.; Ranthe, M.F.; Jódar, E. Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial. Diabetes Obes. Metab., 2018, 20(1), 200-205.
[http://dx.doi.org/10.1111/dom.13043] [PMID: 28643425]
[74]
Hunt, B.; Mocarski, M.; Valentine, W.J.; Langer, J. Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA. J. Med. Econ., 2017, 20(7), 663-670.
[http://dx.doi.org/10.1080/13696998.2017.1301943] [PMID: 28294641]
[75]
Hunt, B.; Glah, D.; van der Vliet, M. Modeling the long-term cost-effectiveness of IDegLira in patients with type 2 diabetes who are failing to meet glycemic targets on basal insulin alone in the Netherlands. Diabetes Ther., 2017, 8(4), 753-765.
[http://dx.doi.org/10.1007/s13300-017-0266-3] [PMID: 28523483]
[76]
Hunt, B.; Mocarski, M.; Valentine, W.J.; Langer, J. IDegLira versus insulin glargine U100: a long-term cost-effectiveness analysis in the US setting. Diabetes Ther., 2017, 8(3), 531-544.
[http://dx.doi.org/10.1007/s13300-017-0251-x] [PMID: 28349444]
[77]
Hunt, B.; Mocarski, M.; Valentine, W.J.; Langer, J. Evaluation of the short-term cost-effectiveness of IDegLira versus continued up-titration of insulin glargine U100 in patients with type 2 diabetes in the USA. Adv. Ther., 2017, 34(4), 954-965.
[http://dx.doi.org/10.1007/s12325-017-0502-2] [PMID: 28281218]
[78]
Lingvay, I.; Handelsman, Y.; Linjawi, S.; Vilsbøll, T.; Halladin, N.; Ranc, K.; Liebl, A. Efficacy and safety of iDegLira in older patients with type 2 diabetes. Endocr. Pract., 2019, 25(2), 144-155.
[http://dx.doi.org/10.4158/EP-2018-0284] [PMID: 30383495]
[79]
Handelsman, Y.; Chovanes, C.; Dex, T.; Giorgino, F.; Skolnik, N.; Souhami, E.; Stager, W.; Niemoeller, E.; Frias, J.P. Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes. J. Diabetes Complications, 2019, 33(3), 236-242.
[http://dx.doi.org/10.1016/j.jdiacomp.2018.11.009] [PMID: 30600136]
[80]
Miller, E.; Doshi, A.; Grøn, R.; Jódar, E.; Őrsy, P.; Ranthe, M.F.; Sugimoto, D.; Tentolouris, N.; Viljoen, A.; Billings, L.K. IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy. Diabetes Obes. Metab., 2019, 21(12), 2643-2650.
[http://dx.doi.org/10.1111/dom.13851] [PMID: 31385425]
[81]
Meneghini, L. Insulin degludec/liraglutide (IDegLira) maintains glycemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin. Diabet. Med., 2019, 37(2), 267-276.
[http://dx.doi.org/10.1111/dme.14178] [PMID: 31705547]
[82]
Taybani, Z.; Bótyik, B.; Katkó, M.; Gyimesi, A.; Várkonyi, T. simplifying complex insulin regimens while preserving good glycemic control in type 2 diabetes. Diabetes Ther., 2019, 10(5), 1869-1878.
[http://dx.doi.org/10.1007/s13300-019-0673-8] [PMID: 31347100]
[83]
Torre, E.; Bruno, G.M.; Di Matteo, S.; Martinotti, C.; Oselin, M.; Valentino, M.C.; Parodi, A.; Bottaro, L.C.; Colombo, G.L. Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes. Clinicoecon. Outcomes Res., 2018, 10, 413-421.
[http://dx.doi.org/10.2147/CEOR.S169045] [PMID: 30100746]
[84]
Tabák, Á.G. Efficacy and safety of iGlarLixi, fixed-ratio combination of insulin glargine and lixisenatide, compared with basal-bolus regimen in patients with type 2 diabetes: propensity score matched analysis. Diabetes Ther., 2020, 11(1), 305-318.
[http://dx.doi.org/10.1007/s13300-019-00735-7] [PMID: 31848983]
[85]
Yang, T.; Cutshall, B.T.; Tatara, A.; Ruegger, M. Combined insulin and GLP-1 receptor agonists: simplifying treatment or adding obstacles? J. Pharm. Pract., 2019, 32(4), 447-449.
[http://dx.doi.org/10.1177/0897190017753041] [PMID: 30270723]
[86]
Cai, X.; Gao, X.; Yang, W.; Ji, L. Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis. Expert Opin. Pharmacother., 2017, 18(17), 1789-1798.
[http://dx.doi.org/10.1080/14656566.2017.1400011] [PMID: 29090600]
[87]
Evans, M.; Billings, L.K.; Håkan-Bloch, J.; Slothuus, U.; Abrahamsen, T.J.; Andersen, A.; Jansen, J.P. An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin. J. Med. Econ., 2018, 21(4), 340-347.
[http://dx.doi.org/10.1080/13696998.2017.1409228] [PMID: 29164973]
[88]
Pöhlmann, J.; Montagnoli, R.; Lastoria, G.; Parekh, W.; Markert, M.; Hunt, B. Value for money in the treatment of patients with type 2 diabetes mellitus: assessing the long-term cost-effectiveness of iDegLira versus iGlarLixi in Italy. Clinicoecon. Outcomes Res., 2019, 11, 605-614.
[http://dx.doi.org/10.2147/CEOR.S218746] [PMID: 31632108]